| Generic name | Calaspargase pegol-mknl |
| Pronunciation | kal-AS-par-jase PEG-ol mknl |
| Brand name(s), other common name(s) | AsparlasTM |
| Drug type | Asparagine specific enzyme |
| How the drug is given | Intravenous |
Indications and Usage
Calaspargase pegol-mknl is FDA approved as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years.
Side effects needing medical attention
The most common adverse reactions were elevated transaminase (a liver enzyme), bilirubin increased, pancreatitis and abnormal clotting.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.